Zacks
0
All posts from Zacks
Zacks in Our Research. Your Success.,

Why Neos Therapeutics (NEOS) Could Be Positioned for a Surge

Neos Therapeutics, Inc. NEOS is a pharmaceutical company that could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well.

These positive earnings estimate revisions suggest that analysts are becoming more optimistic on NEOS’s earnings for the coming quarter and year. In fact, consensus estimates have moved sharply higher for both of these time frames over the past four weeks, suggesting that Neos Therapeutics could be a solid choice for investors.

Current Quarter Estimates for NEOS

In the past 30 days, 1 estimate has gone higher for Neos Therapeutics, with no downward revisions in the same time period. The trend has been pretty favorable too, with estimates narrowing from a loss of $1.06 a share 30 days ago, to a loss of 87 cents a share today, a move of 17.9%.

Current Year Estimates for NEOS

Meanwhile, Neos Therapeutics’ current year figures are also looking quite promising, with 1 estimate moving higher in the past month, with no downward revisions. The consensus estimate trend has also seen a boost for this time frame, narrowing from a loss of $5.18 per share 30 days ago to a loss of $3.74 per share today, a move of 27.8%.

Bottom Line

The stock has also started to move higher lately, adding 5.7% over the past four weeks, suggesting that investors are starting to take note of this impressive story. So investors may definitely want to consider this Zacks Rank #3 (Hold) stock to profit in the near future.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
NEOS THERAPTCS (NEOS): Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research